VAUGHAN, ON, Aug. 13, 2019 /PRNewswire/ - Target Group Inc. ("Target Group" or the "Company") (OTCQB: CBDY) is pleased to announce, that effective

CHARLESTON, S.C., Aug. 13, 2019 /PRNewswire/ -- Benefitfocus, Inc. (NASDAQ: BNFT), a

VANCOUVER, British Columbia and MENLO PARK, Calif., Aug. 13, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar"

LAS VEGAS, Aug. 13, 2019 /PRNewswire/ -- Digipath, Inc. (OTCQB: DIGP) ("DIGP" or the "Company"), a service-oriented independent testing laboratory, data analytics and

SAN FRANCISCO, Aug. 13, 2019 /PRNewswire/ -- Today, American Logistics Company (ALC) announced a partnership with Uber Health, which is the rideshare company's first national collaboration with a healthcare transportation management company. The combination of Uber's vast driver-partner network and American Logistics' full-service, turnkey transportation solution de

INDIANAPOLIS, Aug. 13, 2019 /PRNewswire/ -- Recalls in the second quarter remained flat across industries but serious and deadly incidents were on the rise – an indication of lagging activity by regulatory agencies, according to the 

COLUMBIA, Mo., Aug. 13, 2019 /PRNewswire/ -- WINDGO, Inc., a research and development company specializing in smart material and vibrational transfer technologies, announced today that they have been granted US Patent No. 10,376,423 for an invention that will provide Internet of Things (IoT) sensory and response communications to devices worn on human and anima

Hilsenroth's Hire is Part of the Company's Market Expansion Strategy ATLANTA, Aug. 13, 2019 /PRNewswire/ -- Biolog-id LLC, a world leader in connected health solutions, announced today that the company's board of directors appointed Troy Hilsenroth as CEO. Prior to Mr. Hilsenroth's appointment, Biolog-id President

SAN FRANCISCO, Aug. 13, 2019 /PRNewswire/ -- New West Summit 2019 (NWS5) THE Cannabis Tech Conference (October 10-11, 2019) is pleased to announce k

DENVER, Aug. 13, 2019 /PRNewswire/ -- KromaTiD, Inc. announced today that it has successfully completed its A round of financing with Denver-based firm First Capital Ventures. KromaTiD's traction and potential within the gene editing market have enabled the company to close this round at 100% oversubscription. This funding will ena